Wolfgang Miesbach/LinkedIn
May 13, 2026, 15:10
Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Rethinking Bleeding Risk in Anticoagulation.
At the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo delivered a fantastic talk on bleeding risk in patients receiving antithrombotic therapy – from AF and VTE to prosthetic valves, LV thrombus and acute coronary syndromes:
- Antithrombotic therapy is used across many indications, so managing bleeding risk is a daily challenge in routine practice.
- Major bleeding (incl. ICH) remains a major limitation of VKAs and DOACs, and ‘fear‑driven’ underdosing in real life is still common.
- High‑risk patients (age, renal impairment, prior bleeding) live within a narrow therapeutic window, making individualized decisions essential.
- Targeting FXI could help decouple thrombosis from hemostasis, with early data suggesting relevant bleeding reduction while preserving efficacy.”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments